Welcome to QBiotics

• We are an unlisted Australian public company.
• We discover, develop and commercialise novel anticancer and wound healing pharmaceuticals for human and veterinary markets.
• Our lead drug, tigilanol tiglate, is a small molecule anticancer pharmaceutical targeting a range of solid tumours across multiple species.
• The simultaneous development of products for both the vet and human markets enables validation of technology and reduces risks for human development, while generating early revenues.

Read more